A new Alzheimer type dementia diagnostic treatment has been approved in Korea, the first time in Asia
After the FDA in the U.S. and the EMA in Europe, a new Alzheimer type dementia treatment has been permitted by the Ministry of Food and Drug Safety for the third time.
The new drug, titled ‘Nuraceq (Flobetaben F18)’, is a radiopharmaceutical used in PET/CT scans, which the German company, Bayer,...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
